Positive News SentimentPositive NewsNASDAQ:CTKB Cytek Biosciences (CTKB) Stock Price, News & Analysis $2.42 -0.03 (-1.22%) Closing price 04:00 PM EasternExtended Trading$2.42 0.00 (-0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cytek Biosciences Stock (NASDAQ:CTKB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cytek Biosciences alerts:Sign Up Key Stats Today's Range$2.37▼$2.4650-Day Range$2.45▼$4.2452-Week Range$2.36▼$7.63Volume905,371 shsAverage Volume735,099 shsMarket Capitalization$306.51 millionP/E RatioN/ADividend YieldN/APrice Target$5.25Consensus RatingHold Company OverviewCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Read More… Cytek Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCTKB MarketRank™: Cytek Biosciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 663rd out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingCytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageCytek Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Cytek Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -30.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -30.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cytek Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.65% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Cytek Biosciences has recently increased by 1.21%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.65% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Cytek Biosciences has recently increased by 1.21%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.29 News SentimentCytek Biosciences has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CTKB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Cytek Biosciences is held by insiders.Percentage Held by Institutions69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cytek Biosciences' insider trading history. Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Stock News HeadlinesThe Goldman Sachs Group Cuts Cytek Biosciences (NASDAQ:CTKB) Price Target to $3.00May 15, 2025 | americanbankingnews.comCytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 23, 2025 | Paradigm Press (Ad)Cytek Biosciences: Earnings Call Reveals Mixed FortunesMay 9, 2025 | tipranks.comCytek Biosciences Reports Q1 2025 Financial ResultsMay 9, 2025 | tipranks.comCytek Biosciences Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comCytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?May 5, 2025 | seekingalpha.comCytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025April 29, 2025 | globenewswire.comSee More Headlines CTKB Stock Analysis - Frequently Asked Questions How have CTKB shares performed this year? Cytek Biosciences' stock was trading at $6.49 at the beginning of the year. Since then, CTKB stock has decreased by 62.8% and is now trading at $2.4150. View the best growth stocks for 2025 here. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The business had revenue of $41.46 million for the quarter, compared to analyst estimates of $43.18 million. Cytek Biosciences had a negative net margin of 5.05% and a negative trailing twelve-month return on equity of 2.58%. Read the conference call transcript. How will Cytek Biosciences' stock buyback program work? Cytek Biosciences' Board of Directors initiated a stock buyback plan on Monday, December 30th 2024, which authorizes the company to buy back $50,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 5.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued. When did Cytek Biosciences IPO? Cytek Biosciences (CTKB) raised $248 million in an IPO on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share. Who are Cytek Biosciences' major shareholders? Cytek Biosciences' top institutional shareholders include Vanguard Group Inc. (7.54%), Topline Capital Management LLC (1.15%), Goldman Sachs Group Inc. (0.91%) and Charles Schwab Investment Management Inc. (0.87%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod and Jack Ball. View institutional ownership trends. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytek Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings5/08/2025Today5/23/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:CTKB CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Target$5.25 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside+117.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,150,000.00 Net Margins-5.05% Pretax Margin-5.92% Return on Equity-2.58% Return on Assets-2.05% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio5.47 Sales & Book Value Annual Sales$197.05 million Price / Sales1.55 Cash Flow$0.01 per share Price / Cash Flow206.16 Book Value$2.90 per share Price / Book0.83Miscellaneous Outstanding Shares126,659,000Free Float116,445,000Market Cap$305.88 million OptionableOptionable Beta1.42 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CTKB) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.